Results 111 to 120 of about 3,492,883 (216)

Targeting EphA2 with miR‐124 mediates Erlotinib resistance in K‐RAS mutated pancreatic cancer

The Journal of pharmacy and pharmacology, 2019
Chemotheraputic drug resistance is a critical factor associated with the poor survival in advanced/metastatic pancreatic cancer (PC) patients.
Jing Du, Yuanqiao He, Weiquan Wu, Pengcheng Li, Youwei Chen, Z. Hu, Yong Han   +6 more
semanticscholar   +1 more source

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment

BMC Cancer, 2018
Background Lung cancer patients with an activating mutation in the EGFR (epidermal growth factor receptor) can develop resistance to erlotinib treatment, which is often mediated by the T790M resistance mutation in EGFR.
Christina Demuth, Anne Tranberg Madsen, Britta Weber, Lin Wu, Peter Meldgaard, Boe Sandahl Sorensen   +5 more
doaj   +1 more source

Unique Molecular Features in High-Risk Histology Endometrial Cancers [PDF]

, 2019
Endometrial cancer is the most common gynecologic malignancy in the United States and the sixth most common cancer in women worldwide. Fortunately, most women who develop endometrial cancer have low-grade early-stage endometrioid carcinomas, and simple ...
Collins, Kaitlyn, Hawkins, Shannon M., Jones, Devin E., Pandita, Pooja, Wang, Xiyin   +4 more
core   +1 more source

Novel therapeutic targets in NSCLC resistance to Erlotinib

, 2017
Approximately 10% of non-small cell lung cancers (NSCLCs) have an activating mutation within the kinase domain of epidermal growth factor receptor (EGFR). Competitive tyrosine kinase inhibitors (TKIs), such as Erlotinib and Gefitinib, have been developed to therapeutically exploit this.
openaire   +3 more sources

Empirical Osimertinib as a Second‐Line Treatment Is a Viable Option Following First‐ and Second‐Generation TKI Therapy With Unknown EGFR Status in Treated Non‐Small Cell Lung Cancer: A Retrospective Study

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background and Purpose Patients with advanced epidermal growth factor receptor (EGFR)‐mutated adenocarcinoma often receive frontline first‐ and second‐generation EGFR tyrosine kinase inhibitor (TKI) treatments in Taiwan. However, upon progression, not all patients undergo rebiopsy for molecular testing.
Min‐Hsi Lin, Kuo‐An Chu, Chiu‐Fan Chen, You‐Cheng Jiang, Wei‐Cheng Hong, Ming‐Yen Hung, Chun‐Hsiang Hsu   +6 more
wiley   +1 more source

Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors

Journal for ImmunoTherapy of Cancer, 2019
Background Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) like erlotinib are effective for treating patients with EGFR mutant lung cancer; however, drug resistance inevitably emerges.
Deborah Ayeni, Braden Miller, Alexandra Kuhlmann, Ping-Chih Ho, Camila Robles-Oteiza, Mmaserame Gaefele, Stellar Levy, Fernando J. de Miguel, Curtis Perry, Tianxia Guan, Gerald Krystal, William Lockwood, Daniel Zelterman, Robert Homer, Zongzhi Liu, Susan Kaech, Katerina Politi   +16 more
doaj   +1 more source

Primary Erlotinib Resistance in a Patient with Non-Small Cell Lung Cancer Carrying Simultaneous Compound EGFR L718A, Q849H, and L858R Mutations

Biomolecular Concepts, 2021
Nowadays, mutations in the epidermal growth factor receptor (EGFR) kinase domain are studied in targeted therapy of non-small cell lung cancer (NSCLC) with EGFR tyrosine kinase inhibitors including gefitinib and erlotinib.
Mirtavoos-mahyari Hanifeh, Rismani Elham, Lotfabadi Alireza Sarkar, Dezfouli Azizollah Abbasi, Sheikhy Kambiz, Dezfuli Mojtaba Mokhber, Heshmatnia Jalal   +6 more
doaj   +1 more source

High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. [PDF]

, 2016
Hundreds of genetically characterized cell lines are available for the discovery of genotype-specific cancer vulnerabilities. However, screening large numbers of compounds against large numbers of cell lines is currently impractical, and such experiments
A Basu, Alykhan F Shamji, Andrew Crenshaw, Andrew L Kung, Aristotle M Mannan, Aviad Tsherniak, Bang Wong, Barbara A Weir, Bradley R Taylor, C Ditchfield, Channing Yu, D Peck, E Comer, Griselda Metta Yvone, J Barretina, J Du, JM Korn, Joshua Z Gould, JP Koivunen, JT Lowe, Kenneth N Ross, KT Flaherty, LA Marcaurelle, Levi A Garraway, M Carmena, Melissa A Marton, MI Davis, Michael A Foley, Michelle A Palmer, MJ Garnett, MK Muellner, ML Sos, MW Karaman, NC Turner, OD Abaan, Pablo Tamayo, PD Andrews, SL Schreiber, SM Wilhelm, Stuart L Schreiber, SV Sharma, Todd R Golub, U McDermott, Wendy Winckler, XD Zhang, Yan-Ling Zhang   +45 more
core   +2 more sources

Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib [PDF]

Cancer Biology & Therapy, 2010
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, are the first targeted therapy drugs approved for the treatment of advanced non-small-cell lung cancer (NSCLC). Interestingly, treatment with these small molecule, reversible EGFR-TKIs leads to more positive response rates in patients with ...
Yan, Xu, Hongyu, Liu, Jun, Chen, Qinghua, Zhou   +3 more
openaire   +2 more sources

Pulmonary Cryptococcal Infection Complicating Gefitinib Therapy in a Patient With EGFR L858R‐Positive Lung Adenocarcinoma: A Case Report

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT In patients with EGFR‐mutant lung adenocarcinoma receiving gefitinib or other EGFR‐TKIs, the development of new pulmonary nodules should not be hastily attributed to disease progression; secondary pulmonary cryptococcosis should be considered in the differential diagnosis.
Yun Wang, Qianyu Wang, Jiangrong Liao, Yuxiang Zhou, Fang Yang, Gui feng Li, Chunyan Wu, Ting Jiang   +7 more
wiley   +1 more source